Latest News

STAT Plus: Pharmalittle: Jacobus price for rare disease drug sets up battle with rival Catalyst; Repatha called cost-effective

Good morning. Elizabeth Cooney here, minding the Pharmalittle store today. Ed will be back tomorrow, but here’s what’s brewing today.

After weeks of anticipation, Jacobus Pharmaceutical has priced its rare disease drug at $80 a tablet, or less than half the price of a similar pill sold by its upstart rival, Catalyst Pharmaceuticals (CPRX), STAT informs us. The move is likely to set up a closely watched battle between a small, family-run drug maker that used to supply the drug for free and a newcomer that secured seven years’ patent protection before Jacobus won FDA approval for a pediatric version.

Continue to STAT Plus to read the full story…

Source link

Related posts

Medical News Today: Simply thinking of your partner can help you manage stress


Owning a dog is influenced by genetic make-up


Medical News Today: Managing psoriasis on the feet


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy